Showing results (61-70 of 93) with videos related to
Sort By:
Pageof 10
The Oncologist|August 4, 2016
Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of ExperienceYingqiang Zhang, Guihua Huang, Yu Wang, et al.Applied Optics|March 16, 2007
Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapyYong-Eun Lee Koo, Wenzhe Fan, Hoejin Hah, et al.Analytical Chemistry|September 21, 2010
Near infrared luminescent oxygen nanosensors with nanoparticle matrix tailored sensitivityYong-Eun Koo Lee, Elyse E Ulbrich, Gwangseong Kim, et al.Cancer Research and Treatment|April 2, 2020
Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular CarcinomaMiao Xue, Yanqin Wu, Wenzhe Fan, et al.Oncotarget|June 21, 2015
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete responseYingqiang Zhang, Wenzhe Fan, Kangshun Zhu, et al.Annals of Translational Medicine|December 14, 2020
The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinomaLixin Ke, Rui Shen, Wenzhe Fan, et al.Clinical Therapeutics|July 16, 2019
Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective StudyWenzhe Fan, Guosheng Yuan, Huishuang Fan, et al.Frontiers in Oncology|January 4, 2024
Efficacy of radiation plus transarterial chemoembolization and lenvatinib in hepatocellular carcinoma with portal vein tumor thrombusAoran Dong, Meiyan Zhu, Zeyu Zhang, et al.Cancer Medicine|June 14, 2022
Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysisWenzhe Fan, Bowen Zhu, Shufan Yue, et al.Pageof 10